We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Read MoreHide Full Article
Key Takeaways
Ironwood expects Linzess to remain its primary growth driver, supporting revenue growth in 2026.
Recent pediatric label expansion and continued prescription demand are expected to lift profits.
Lower rebates tied to pricing changes are expected to support higher net revenues in 2026.
Ironwood Pharmaceuticals’ (IRWD - Free Report) sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent times. The company has a partnership with AbbVie (ABBV - Free Report) to jointly develop and commercialize Linzess in the United States.
Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation (FC) in children and adolescents aged six to 17 years.
Last month, the FDA approved Linzess for the treatment of FC in pediatric patients aged two years and older.
Ironwood’s top line primarily comprises revenues recorded through its collaborative arrangements with ABBV related to the development and commercialization of Linzess in the United States.
IRWD and ABBV equally share Linzess’ brand collaboration profits and losses in the country.
Ironwood also has agreements with Astellas Pharma and AstraZeneca (AZN - Free Report) related to the development and commercialization of Linzess in Japan and China, respectively. Both Astellas Pharma and AstraZeneca pay royalties to Ironwood on net Linzess revenues earned in their regions.
These partnerships provide Ironwood with an additional revenue stream through royalties on Linzess sales outside the United States.
IRWD Expects Linzess to Sustain Sales Momentum in 2026
Ironwood recorded $104.2 million as its share of net profit from U.S. sales, up 169% from the prior year, while total prescription demand grew 5%. Linzess is witnessing strong prescription demand, underscoring management’s optimism for sustained growth in 2026.
Ironwood expects a significant improvement in Linzess’ sales in 2026 and subsequently its share of net profit from the sales of this partnered drug in the United States.
Importantly, earlier this year, Linzess' list price was reduced to support patient access. Despite the reduction, management expects Linzess' net sales to grow year over year in 2026, as the lower list price should reduce certain mandatory government rebates.
As a result, lower rebate payments are expected to drive higher net revenues in 2026.
Ironwood expects total revenues of $450 million to $475 million in 2026. The company expects Linzess to remain its primary growth driver in 2026. Continued prescription demand, the recent pediatric label expansion and favorable pricing dynamics should support higher profit contributions in the upcoming quarters.
IRWD's Price Performance, Valuation and Estimates
Year to date, shares of Ironwood have lost 0.5% compared with the industry’s 8.6% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Ironwood is trading at a discount to the industry. Going by the price-to-sales ratio, the company’s shares currently trade at 1.55, lower than 2.21 for the industry. The stock is trading below its five-year mean of 3.80.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has increased from 98 cents to $1.04 over the past 60 days. During the same time frame, loss per share estimates for 2027 have remained stable at 3 cents.
View the Zacks #1 Rank List
Image: Bigstock
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Key Takeaways
Ironwood Pharmaceuticals’ (IRWD - Free Report) sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent times. The company has a partnership with AbbVie (ABBV - Free Report) to jointly develop and commercialize Linzess in the United States.
Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation (FC) in children and adolescents aged six to 17 years.
Last month, the FDA approved Linzess for the treatment of FC in pediatric patients aged two years and older.
Ironwood’s top line primarily comprises revenues recorded through its collaborative arrangements with ABBV related to the development and commercialization of Linzess in the United States.
IRWD and ABBV equally share Linzess’ brand collaboration profits and losses in the country.
Ironwood also has agreements with Astellas Pharma and AstraZeneca (AZN - Free Report) related to the development and commercialization of Linzess in Japan and China, respectively. Both Astellas Pharma and AstraZeneca pay royalties to Ironwood on net Linzess revenues earned in their regions.
These partnerships provide Ironwood with an additional revenue stream through royalties on Linzess sales outside the United States.
IRWD Expects Linzess to Sustain Sales Momentum in 2026
Ironwood recorded $104.2 million as its share of net profit from U.S. sales, up 169% from the prior year, while total prescription demand grew 5%. Linzess is witnessing strong prescription demand, underscoring management’s optimism for sustained growth in 2026.
Ironwood expects a significant improvement in Linzess’ sales in 2026 and subsequently its share of net profit from the sales of this partnered drug in the United States.
Importantly, earlier this year, Linzess' list price was reduced to support patient access. Despite the reduction, management expects Linzess' net sales to grow year over year in 2026, as the lower list price should reduce certain mandatory government rebates.
As a result, lower rebate payments are expected to drive higher net revenues in 2026.
Ironwood expects total revenues of $450 million to $475 million in 2026. The company expects Linzess to remain its primary growth driver in 2026. Continued prescription demand, the recent pediatric label expansion and favorable pricing dynamics should support higher profit contributions in the upcoming quarters.
IRWD's Price Performance, Valuation and Estimates
Year to date, shares of Ironwood have lost 0.5% compared with the industry’s 8.6% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Ironwood is trading at a discount to the industry. Going by the price-to-sales ratio, the company’s shares currently trade at 1.55, lower than 2.21 for the industry. The stock is trading below its five-year mean of 3.80.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has increased from 98 cents to $1.04 over the past 60 days. During the same time frame, loss per share estimates for 2027 have remained stable at 3 cents.
Image Source: Zacks Investment Research
IRWD's Zacks Rank
Ironwood currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.